Overview

Enhertu DS-8201 changed how teams think about HER2-directed therapy because it delivers cytotoxic payload through an antibody, letting one molecule combine targeting and chemotherapy. For B2B purchasers, the combination conversation is really a scheduling and compatibility conversation. This article walks through the combination logic that drives demand.

How It Works

Fam-trastuzumab deruxtecan is an antibody-drug conjugate pairing an anti-HER2 antibody with a topoisomerase I inhibitor payload. After binding HER2 on the tumor surface, the complex is internalized and the payload is released inside the cell, breaking DNA. A useful property is the bystander effect: payload diffuses to nearby cells, including HER2-low neighbors, widening the treatable population beyond classical HER2-positive disease.

Indications

Enhertu is indicated for unresectable or metastatic HER2-positive breast cancer after prior therapy, for HER2-low breast cancer, and for HER2-positive gastric and other solid tumors per local approvals. Selection depends on HER2 testing by assay, including the HER2-low category that older criteria excluded. It is administered by trained centers because of infusion and monitoring requirements.

Dosage & Administration

The approved regimen is 5.4 mg/kg given as an intravenous infusion every three weeks. Premedication and anti-emetic cover are standard, and ejection-fraction monitoring is required because of cardiac considerations. Infusion must occur in a facility equipped to manage reactions, which shapes how distributors coordinate with hospital pharmacy schedules.

Each three-week visit should be booked with enough lead time to receive the vial and complete pre-infusion checks within the same window.

Storage & Sourcing

Vials are stored at 2 to 8 °C and must not be frozen; protect from light and use within the defined in-use window after reconstitution. Combination planning means syncing Enhertu deliveries with the three-week infusion calendar and confirming cold-chain integrity on arrival. Buyers should track lot-specific expiry closely given the concentrated payload formulation.

Reconstituted solution has a limited in-use period, so prepare only the volume needed for the scheduled infusion to avoid waste.

FAQ

Q: Is Enhertu used together with immunotherapy or chemotherapy? A: It is primarily sequenced or combined per protocol rather than mixed in one line; confirm the exact regimen, because adding agents changes monitoring and sourcing volumes.

Q: How does the bystander effect influence who receives it? A: It allows activity in HER2-low tumors, expanding eligible patients and therefore steady, protocol-driven demand beyond traditional HER2-positive cases.

Q: What cold-chain checks matter at receiving? A: Verify the 2 to 8 °C record, intact light protection, and remaining shelf life; reject any vial exposed to freezing or temperature excursion.